Projects per year
I graduated from St Bartholomew’s Hospital, University of London in 1985 and trained in general medicine and HIV in London and Bristol. In 1988, I joined the MRC HIV Clinical Trials Centre as a Trial Physician for one of the first large scale, international HIV trials. In 1991, I was awarded an MRC training fellowship to continue formal training in clinical trials and epidemiology at the London School of Hygiene and Tropical Medicine.
In 1993, I moved to the Medicines Control Agency to work as a medical epidemiologist in the post marketing drug evaluation unit where I led the investigation of a number of drug safety issues, including a major project on the relative safety of non aspirin NSAIDs. I had the opportunity to develop links with organizations using large databases to investigate drug safety, including those at Boston University and the University of Dundee. Between 1995 and 2000, I continued to work in the area of pharmacovigilance with a period in the US as Medical Epidemiologist with Eli Lilly in Indianapolis and Japan and a period at the Boston Collaborative Drug Surveillance Programme.
In 2000, I returned to the MRC as Senior Scientist/Epidemiologist at the MRC Clinical Trials Unit and began to work on international trials in ovarian and endometrial cancer, where I had the opportunity. In 2010, I completed higher specialist training in Clinical Pharmacology and Therapeutics and was appointed to develop a new clinical trials unit at UCL as Director with wide ranging therapeutic area responsibilities. I then spent a further year in the commercial sector as Managing Director of a specialist pharmacovigilance and drug development company in Cambridge.
In July 2013, I took up the post of Professor of Medicine and Epidemiology at the University of East Anglia and Director of the Norwich Clinical Trials Unit.
Medicine MB, BS London 1985
Membership of Royal College of Physicians MRCP(UK) 1989
MSc Epidemiology, London School of Hygiene and Tropical Medicine 1993
- National collaborations through the National Cancer Research Institute (Gynae Clinical Studies Group Member 2001-2008)
- International collaborations e.g. US NCI, Canadian NCIC and International Gynae Cancer InterGroup
Key Research Interests
My key research interests are in the design, conduct and analysis of practice changing clinical trials in a wide range of therapeutic areas and novel treatments, particularly involving academic/industry collaborations.
Recently completed projects:
ICON7 Bevacizumab in the first line treatment of ovarian cancer
ICON6 (Co-CI) Cediranib in relapsed ovarian cancer
Chorus (Co-CI) Neoadjuvant chemotherapy for advanced ovarian cancer
My main administrative role is Director of the Norwich Clinical Trials Unit.
- I am currently supervising an MD Res student at UCL.
- I will contribute to MBBS teaching and postgraduate teaching and training at UEA.
- I am committed to developing clinical and non clinical staff working on academic clinical trials.
Expertise related to UN Sustainable Development Goals
In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):
Dive into details
Select a country/territory to view shared publications and projects
Initial toxicity assessment of ICON6: a randomised trial of cediranib plus chemotherapy in platinum-sensitive relapsed ovarian cancerRaja, F. A., Griffin, C. L., Qian, W., Hirte, H., Parmar, M. K., Swart, A. M. & Ledermann, J. A., 27 Sep 2011, In: British Journal of Cancer. 105, 7, p. 884-889 6 p.
Research output: Contribution to journal › Article › peer-review53 Citations (Scopus)
Multicentre evaluation of two multiplex PCR platforms for the rapid microbiological investigation of nosocomial pneumonia in UK ICUs: the INHALE WP1 studyINHALE WP1 Study Group, 13 Jan 2022, (E-pub ahead of print) In: Thorax.
Research output: Contribution to journal › Article › peer-reviewOpen AccessFile11 Downloads (Pure)
Cediranib in addition to chemotherapy for women with relapsed platinum-sensitive ovarian cancer (ICON6): overall survival results of a phase III randomised trialLedermann, J. A., Embleton-Thirsk, A. C., Perren, T. J., Jayson, G. C., Rustin, G. J. S., Kaye, S. B., Hirte, H., Oza, A., Vaughan, M., Friedlander, M., González-Martín, A., Deane, E., Popoola, B., Farrelly, L., Swart, A. M., Kaplan, R. S. & Parmar, M. K. B., 1 Apr 2021, In: ESMO Open. 6, 2, 100043.
Research output: Contribution to journal › Article › peer-reviewOpen AccessFile3 Citations (Scopus)9 Downloads (Pure)
Implementing supportive exercise interventions in the colorectal cancer care pathway: a process evaluation of the PREPARE-ABC randomised controlled trialMurdoch, J., Varley, A., McCulloch, J., Jones, M., Thomas, L. B., Clark, A., Stirling, S., Turner, D., Swart, A. M., Dresser, K., Howard, G., Saxton, J. & Hernon, J., 23 Oct 2021, In: BMC Cancer. 21, 1, 1137 .
Research output: Contribution to journal › Article › peer-reviewOpen AccessFile1 Citation (Scopus)4 Downloads (Pure)
INHALE: the impact of using FilmArray Pneumonia Panel molecular diagnostics for hospital-acquired and ventilator-associated pneumonia on antimicrobial stewardship and patient outcomes in UK Critical Care—study protocol for a multicentre randomised controlled trialHigh, J., Enne, V. I., Barber, J. A., Brealey, D., Turner, D. A., Horne, R., Peters, M., Dhesi, Z., Wagner, A. P., Pandolfo, A. M., Stirling, S., Russell, C., O’Grady, J., Swart, A. M., Gant, V. & Livermore, D. M., 7 Oct 2021, In: Trials. 22, 1, 680 .
Research output: Contribution to journal › Article › peer-reviewOpen AccessFile1 Citation (Scopus)3 Downloads (Pure)